Orchid Pharma Limited — Investor Meet, 15-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance:** Orchid Pharma reported total income of ₹227 crores and an EBITDA of ₹37 crores for Q3 FY '25. Over the first nine months, total income reached ₹710 crores, marking a 15% year-over-year increase. EBITDA for the same period stood at ₹115 crores, up from ₹99 crores the previous year, while profit after tax (PAT) improved from ₹62 crores to ₹78 crores, representing a notable 26% growth. Despite a volume increase of over 20%, price corrections in key products resulted in muted total sales.

2. **Future Outlook and Growth Drivers:** Management emphasized a long-term growth vision, focusing on market realignment and operational excellence. They foresee strong future prospects, bolstered by successful product launches, particularly in the antimicrobial sector, and ongoing investments in R&D and regulatory compliance.

3. **Order Book and Operational Updates:** The recent EU GMP audit yielded a compliance certificate, although incurred costs temporarily increased expenses by ₹3 crores. The 7ACA project to enhance API capabilities is progressing well, with major equipment orders expected completed by Q1 FY '26.

4. **Analyst Q&A Insights:**

- **Revenue and Profitability:** Analysts expressed concern over price corrections affecting core product lines. Management reassured that long-term gross margins will remain stable, despite short-term fluctuations.

- **Market Position and Competitive Landscape:** Queries highlighted competition's impact, particularly concerning price adjustments and market share amidst foreign competition.

- **Operational Challenges or Risks:** Management acknowledged potential supply chain and cost pressures but reiterated confidence in navigating these effectively.

- **Capex and Capital Allocation:** Discussions focused on current cash reserves of ₹194 crores yielding around 7% interest, with planned strategic spending on key projects.

- **Strategic Priorities and Long-Term Vision:** Analysts queried long-term growth expectations, leading management to reaffirm their commitment to achieving 20% CAGR over the next few years.

5. **Market or Regulatory Updates:** Management confirmed ongoing monitoring of regulatory interactions, particularly with the USFDA, but did not disclose specific timelines for forthcoming approvals.

6. **Strategic Focus Areas:** The company maintains emphasis on sustainable growth, innovation, and strategic market penetration, as evidenced by their commitment to robust operational frameworks.

7. **Investor Insight:** The company's financial health and growth trajectory, alongside strategic initiatives in key product areas, suggest a preference for sustained engagement in the stock, aligning more closely with a ‘buy’ position in the longer term, given the current developments and future outlook.